⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Keymed Biosciences and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Keymed Biosciences
↗Chengdu, China
Keymed Biosciences is a China-based, integrated biotechnology company focused on the in-house discovery and development of innovative biological therapies. The company specializes in addressing large, underserved medical needs in the autoimmune and oncology therapeutic areas, utilizing a fully integrated R&D platform that spans discovery to manufacturing.
Since its founding in 2016, Keymed has transitioned from an R&D-focused entity to a commercial-stage company. It has built a robust pipeline of over 50 programs, including multiple clinical-stage assets, and has established significant international partnerships, including licensing deals with major pharmaceutical companies like AstraZeneca and collaborations involving its bispecific antibody and ADC platforms.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology and Autoimmune Biotech
SIZE & FINANCIALS
Employees:501-1000
Revenue:$100M
Founded:2016
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:OrbiMed, Bain Capital
STOCK
Exchange:HKEX
Ticker:02162
Market Cap:$2.22B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Monoclonal antibody, Bispecific antibody, Antibody drug conjugate (ADC), siRNA
Active Trials:26
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AstraZeneca (CMG901 licensing), Rona Therapeutics (siRNA collaboration), Gilead Sciences (in-licensed program gamgertamig)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Bo Chen - Founder and CEO
Scientific Founders:Bo Chen
LINKS
Website:keymedbio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Keymed Biosciences. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.